Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies

Table 6

Pharmacokinetic studies of selected formulations.

Formulation	𝐶max	𝑇max	AUC	AUMC	𝐾el	𝑇1/2	MRT	RB
	(𝜇g/mL)	(hrs)	(𝜇g·hr/mL)	(𝜇g·hr^2/mL)	(h^−1)	(hr)	(hr)	(%)
ES	0.791±0.33	1±0.11	7.186±1.2	57.08±2.7	0.084	8.25±1.2	11.9
EMF	1.65±0.94	2±0.27	20.22±1.5	198.4±2.2	0.077	8.98±1.1	12.98
ESLN-3	4.21±0.63	6±0.17	79.2±1.1	866.6±3.5	0.0263	26.65±0.78	38.48	391.69*

∗Relative bioavailability with respect to EMF.
(i) AUMC: area under the first moment curve; MRT: mean residence time; 𝐾_el: elimination rate constant; RB: relative bioavailability.
(ii) EMF, ES, and ESLN-3 are formulations containing Efavirenz equivalent to 10 mg.
All data expressed as mean ± S.D, 𝑛=6 (𝑃≤0.05).